CA2648648A1 - Cellules derivees du derme pour des applications de genie histologique - Google Patents
Cellules derivees du derme pour des applications de genie histologique Download PDFInfo
- Publication number
- CA2648648A1 CA2648648A1 CA002648648A CA2648648A CA2648648A1 CA 2648648 A1 CA2648648 A1 CA 2648648A1 CA 002648648 A CA002648648 A CA 002648648A CA 2648648 A CA2648648 A CA 2648648A CA 2648648 A1 CA2648648 A1 CA 2648648A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- aggrecan
- asid
- tissue
- coated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000004207 dermis Anatomy 0.000 title claims abstract description 30
- 210000004027 cell Anatomy 0.000 claims abstract description 322
- 102000016284 Aggrecans Human genes 0.000 claims abstract description 166
- 108010067219 Aggrecans Proteins 0.000 claims abstract description 166
- 210000001612 chondrocyte Anatomy 0.000 claims abstract description 78
- 238000000034 method Methods 0.000 claims abstract description 59
- 238000010899 nucleation Methods 0.000 claims abstract description 10
- 230000024245 cell differentiation Effects 0.000 claims abstract description 4
- 230000001939 inductive effect Effects 0.000 claims abstract description 4
- 239000000017 hydrogel Substances 0.000 claims description 39
- 229920000936 Agarose Polymers 0.000 claims description 19
- 241000124008 Mammalia Species 0.000 claims description 4
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 claims description 3
- 210000003041 ligament Anatomy 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000000465 moulding Methods 0.000 claims description 3
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims description 3
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 claims description 3
- 210000002435 tendon Anatomy 0.000 claims description 3
- 210000001738 temporomandibular joint Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 210000000689 upper leg Anatomy 0.000 claims 1
- 230000004069 differentiation Effects 0.000 abstract description 7
- 210000002950 fibroblast Anatomy 0.000 description 105
- 210000001519 tissue Anatomy 0.000 description 101
- 239000002609 medium Substances 0.000 description 58
- 230000014509 gene expression Effects 0.000 description 49
- 210000000845 cartilage Anatomy 0.000 description 43
- 102000007469 Actins Human genes 0.000 description 32
- 108010085238 Actins Proteins 0.000 description 32
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 32
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 32
- 210000002744 extracellular matrix Anatomy 0.000 description 32
- 102000000503 Collagen Type II Human genes 0.000 description 31
- 108010041390 Collagen Type II Proteins 0.000 description 31
- 102000012422 Collagen Type I Human genes 0.000 description 26
- 108010022452 Collagen Type I Proteins 0.000 description 26
- 229920002683 Glycosaminoglycan Polymers 0.000 description 25
- 239000004793 Polystyrene Substances 0.000 description 25
- 230000002648 chondrogenic effect Effects 0.000 description 25
- 229920002223 polystyrene Polymers 0.000 description 25
- 102000008186 Collagen Human genes 0.000 description 22
- 108010035532 Collagen Proteins 0.000 description 22
- 102000003970 Vinculin Human genes 0.000 description 22
- 108090000384 Vinculin Proteins 0.000 description 22
- 229920001436 collagen Polymers 0.000 description 22
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 22
- 239000002953 phosphate buffered saline Substances 0.000 description 22
- 238000001338 self-assembly Methods 0.000 description 20
- 238000010186 staining Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 230000008569 process Effects 0.000 description 18
- 229940096422 collagen type i Drugs 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- 238000001514 detection method Methods 0.000 description 16
- 239000011159 matrix material Substances 0.000 description 14
- 230000009816 chondrogenic differentiation Effects 0.000 description 13
- 238000009826 distribution Methods 0.000 description 13
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 13
- 239000011248 coating agent Substances 0.000 description 12
- 238000000576 coating method Methods 0.000 description 12
- 230000008520 organization Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 102000016611 Proteoglycans Human genes 0.000 description 10
- 108010067787 Proteoglycans Proteins 0.000 description 10
- 210000001188 articular cartilage Anatomy 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241000283707 Capra Species 0.000 description 8
- 230000008619 cell matrix interaction Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 229920001287 Chondroitin sulfate Polymers 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 229940094517 chondroitin 4-sulfate Drugs 0.000 description 6
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 6
- 230000003328 fibroblastic effect Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000008521 reorganization Effects 0.000 description 6
- 210000003518 stress fiber Anatomy 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 230000022159 cartilage development Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 108010007093 dispase Proteins 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000007667 floating Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000003068 molecular probe Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 238000007747 plating Methods 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- 238000010240 RT-PCR analysis Methods 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000003436 cytoskeletal effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000001650 focal adhesion Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000004264 monolayer culture Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012876 topography Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 3
- 108010009711 Phalloidine Proteins 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 210000004292 cytoskeleton Anatomy 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002962 histologic effect Effects 0.000 description 3
- 102000054350 human CHI3L1 Human genes 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 230000024121 nodulation Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000010223 real-time analysis Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 238000007790 scraping Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000037716 Chondroitin-sulfate-ABC endolyases Human genes 0.000 description 2
- 108090000819 Chondroitin-sulfate-ABC endolyases Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 2
- 230000000181 anti-adherent effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- AGSPXMVUFBBBMO-UHFFFAOYSA-N beta-aminopropionitrile Chemical compound NCCC#N AGSPXMVUFBBBMO-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000003848 cartilage regeneration Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000005499 meniscus Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008844 regulatory mechanism Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 108700038288 rhodamine-phalloidin Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 description 1
- 101150021507 COL2 gene Proteins 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 206010061762 Chondropathy Diseases 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-ZZWDRFIYSA-N L-glucose Chemical compound OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-ZZWDRFIYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229940121922 Lysyl oxidase inhibitor Drugs 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- 229940123924 Protein kinase C inhibitor Drugs 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- GPKUGWDQUVWHIC-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.NNC1=CC=C(C=C1)C1=CC=C(NN)C=C1 GPKUGWDQUVWHIC-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000011227 chondrocyte hypertrophy Effects 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000007646 directional migration Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VYLDPSVXLWTIAJ-HNNXBMFYSA-N n-[(1s)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide Chemical compound N([C@@H](C(C)C)C(=O)NC=1C=CN=CC=1)C(=O)C1CCCCC1 VYLDPSVXLWTIAJ-HNNXBMFYSA-N 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003881 protein kinase C inhibitor Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000013424 sirius red staining Methods 0.000 description 1
- 230000005476 size effect Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000012358 sourcing Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/76—Agarose, agar-agar
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Urology & Nephrology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Prostheses (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78985106P | 2006-04-05 | 2006-04-05 | |
| US78985506P | 2006-04-05 | 2006-04-05 | |
| US78985306P | 2006-04-05 | 2006-04-05 | |
| US60/789,851 | 2006-04-05 | ||
| US60/789,853 | 2006-04-05 | ||
| US60/789,855 | 2006-04-05 | ||
| PCT/US2007/066085 WO2007136936A2 (fr) | 2006-04-05 | 2007-04-05 | Cellules dérivées du derme pour des applications de génie histologique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2648648A1 true CA2648648A1 (fr) | 2007-11-29 |
Family
ID=38564326
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002648327A Abandoned CA2648327A1 (fr) | 2006-04-05 | 2007-04-05 | Genie tissulaire a l'aide de cellules souches embryonnaires humaines |
| CA002648332A Abandoned CA2648332A1 (fr) | 2006-04-05 | 2007-04-05 | Approche basee sur la forme pour ingenierie tissulaire sans echafaudage |
| CA002648648A Abandoned CA2648648A1 (fr) | 2006-04-05 | 2007-04-05 | Cellules derivees du derme pour des applications de genie histologique |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002648327A Abandoned CA2648327A1 (fr) | 2006-04-05 | 2007-04-05 | Genie tissulaire a l'aide de cellules souches embryonnaires humaines |
| CA002648332A Abandoned CA2648332A1 (fr) | 2006-04-05 | 2007-04-05 | Approche basee sur la forme pour ingenierie tissulaire sans echafaudage |
Country Status (4)
| Country | Link |
|---|---|
| EP (3) | EP2007312A4 (fr) |
| AU (3) | AU2007234365A1 (fr) |
| CA (3) | CA2648327A1 (fr) |
| WO (3) | WO2007136936A2 (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1691727B1 (fr) | 2003-12-11 | 2011-07-06 | Isto Technologies Inc. | Systeme chondral particulaire |
| WO2005081970A2 (fr) | 2004-02-24 | 2005-09-09 | The Curators Of The University Of Missouri | Agregats cellulaires d'auto-assemblage et procedes de fabrication de tissu genetiquement modifies utilisant de tels agregats |
| US20110212894A1 (en) * | 2004-07-09 | 2011-09-01 | Athanasiou Kyriacos A | Decellularization method for scaffoldless tissue engineered articular cartilage or native cartilage tissue |
| WO2010022074A1 (fr) * | 2008-08-18 | 2010-02-25 | William Marsh Rice University | Procédé de décellularisation pour cartilage articulaire modifié de tissu sans échafaudage ou pour tissu de cartilage natif |
| EP1916964A4 (fr) | 2005-08-26 | 2015-11-04 | Zimmer Inc | Implants et procedes pour la reparation, le remplacement et le traitement de maladies articulaires |
| US8163549B2 (en) | 2006-12-20 | 2012-04-24 | Zimmer Orthobiologics, Inc. | Method of obtaining viable small tissue particles and use for tissue repair |
| EP2134297B1 (fr) | 2007-04-12 | 2017-03-08 | Zimmer, Inc. | Dispositif de réparation de tissu |
| EP2254508A4 (fr) * | 2008-03-03 | 2012-03-28 | Univ Rice William M | Procédés de fabrication d'un cartilage amélioré d'ingénierie tissulaire |
| SI2310491T1 (en) * | 2008-06-20 | 2018-07-31 | Universiteit Maastricht | Only composite tissue modules |
| JP5624981B2 (ja) | 2008-06-24 | 2014-11-12 | ザ・キュレーターズ・オブ・ザ・ユニバーシティ・オブ・ミズーリＴｈｅ Ｃｕｒａｔｏｒｓ Ｏｆｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｓｓｏｕｒｉ | 自己集合性多細胞体、および前記多細胞体を用いて３次元の生物構造体を作製する方法 |
| SG177694A1 (en) * | 2009-07-16 | 2012-02-28 | Biotime Inc | Methods and compositions for in vitro and in vivo chondrogenesis |
| US9149952B2 (en) | 2010-10-21 | 2015-10-06 | Organovo, Inc. | Devices, systems, and methods for the fabrication of tissue |
| WO2013010045A1 (fr) | 2011-07-12 | 2013-01-17 | Biotime Inc. | Nouveaux procédés et formulations pour thérapie cellulaire orthopédique |
| US9499779B2 (en) | 2012-04-20 | 2016-11-22 | Organovo, Inc. | Devices, systems, and methods for the fabrication of tissue utilizing UV cross-linking |
| US20140178343A1 (en) | 2012-12-21 | 2014-06-26 | Jian Q. Yao | Supports and methods for promoting integration of cartilage tissue explants |
| US9442105B2 (en) | 2013-03-15 | 2016-09-13 | Organovo, Inc. | Engineered liver tissues, arrays thereof, and methods of making the same |
| WO2015017579A1 (fr) | 2013-07-31 | 2015-02-05 | Organovo, Inc. | Dispositifs, systèmes et procédés automatisés pour la fabrication de tissus |
| EP3126490B1 (fr) | 2014-04-04 | 2020-09-30 | Organovo, Inc. | Tissu mammaire tridimensionnel artificiel, tissu adipeux, et modèle de maladies tumorales |
| US9670443B2 (en) | 2014-06-25 | 2017-06-06 | University Of Leeds | Tissue engineered constructs |
| KR20170064547A (ko) | 2014-10-06 | 2017-06-09 | 오가노보, 인크. | 조작된 신장 조직, 이의 어레이, 및 이를 제조하는 방법 |
| US11529436B2 (en) | 2014-11-05 | 2022-12-20 | Organovo, Inc. | Engineered three-dimensional skin tissues, arrays thereof, and methods of making the same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1051597A (en) * | 1995-11-09 | 1997-05-29 | University Of Massachusetts | Tissue re-surfacing with hydrogel-cell compositions |
| CA2364415A1 (fr) * | 1999-03-02 | 2000-09-08 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Lignees cellulaires embryonnaires ou de type souche produites par transplantation nucleaire d'especes croisees |
| JP2004504834A (ja) * | 2000-08-01 | 2004-02-19 | イスム リサーチ ディベロップメント カンパニー | 胚性細胞の定方向分化 |
| US20020132346A1 (en) * | 2001-03-08 | 2002-09-19 | Jose Cibelli | Use of RNA interference for the creation of lineage specific ES and other undifferentiated cells and production of differentiated cells in vitro by co-culture |
| US20030109038A1 (en) * | 2001-12-07 | 2003-06-12 | Thies R. Scott | Chondrocyte precursors derived from human embryonic stem cells |
| US20020106625A1 (en) * | 2002-02-07 | 2002-08-08 | Hung Clark T. | Bioreactor for generating functional cartilaginous tissue |
| WO2003084385A2 (fr) * | 2002-04-02 | 2003-10-16 | William Marsh Rice University | Cellules redifferenciees utilisees pour reparer les defauts du cartilage |
| US20040082063A1 (en) * | 2002-10-18 | 2004-04-29 | Reliance Life Sciences Pvt. Ltd. | Tissue-like organization of cells and macroscopic tissue-like constructs, generated by macromass culture of cells, and the method of macromass culture |
| EP1819290B1 (fr) * | 2004-07-09 | 2011-03-02 | William Marsh Rice University | Constructions sans echafaudage pour genie tissulaire de cartilage articulaire |
-
2007
- 2007-04-05 CA CA002648327A patent/CA2648327A1/fr not_active Abandoned
- 2007-04-05 CA CA002648332A patent/CA2648332A1/fr not_active Abandoned
- 2007-04-05 EP EP20070760209 patent/EP2007312A4/fr not_active Withdrawn
- 2007-04-05 WO PCT/US2007/066085 patent/WO2007136936A2/fr active Application Filing
- 2007-04-05 AU AU2007234365A patent/AU2007234365A1/en not_active Abandoned
- 2007-04-05 AU AU2007254048A patent/AU2007254048A1/en not_active Abandoned
- 2007-04-05 EP EP07760205A patent/EP2007875A4/fr not_active Withdrawn
- 2007-04-05 EP EP07760211A patent/EP2007881A4/fr not_active Withdrawn
- 2007-04-05 AU AU2007234366A patent/AU2007234366A1/en not_active Abandoned
- 2007-04-05 WO PCT/US2007/066089 patent/WO2007115336A2/fr active Application Filing
- 2007-04-05 CA CA002648648A patent/CA2648648A1/fr not_active Abandoned
- 2007-04-05 WO PCT/US2007/066092 patent/WO2007115337A2/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007254048A1 (en) | 2007-11-29 |
| WO2007115337A8 (fr) | 2007-12-13 |
| WO2007136936A2 (fr) | 2007-11-29 |
| WO2007115336A2 (fr) | 2007-10-11 |
| CA2648327A1 (fr) | 2007-10-11 |
| AU2007234365A1 (en) | 2007-10-11 |
| EP2007881A4 (fr) | 2009-07-08 |
| WO2007115336A3 (fr) | 2008-05-22 |
| AU2007234366A1 (en) | 2007-10-11 |
| EP2007881A2 (fr) | 2008-12-31 |
| WO2007115337A2 (fr) | 2007-10-11 |
| EP2007312A4 (fr) | 2012-08-22 |
| EP2007875A4 (fr) | 2009-12-16 |
| WO2007136936A3 (fr) | 2008-10-23 |
| EP2007875A2 (fr) | 2008-12-31 |
| CA2648332A1 (fr) | 2007-10-11 |
| EP2007312A2 (fr) | 2008-12-31 |
| WO2007115337A3 (fr) | 2008-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2648648A1 (fr) | Cellules derivees du derme pour des applications de genie histologique | |
| Chen et al. | Stepwise differentiation of human embryonic stem cells promotes tendon regeneration by secreting fetal tendon matrix and differentiation factors | |
| US20090142307A1 (en) | Shape-Based Approach for Scaffoldless Tissue Engineering | |
| EP3397294B1 (fr) | Procédé de préparation de bloc organoïde cartilagineux 3d | |
| CN100571791C (zh) | 人工关节的制造方法 | |
| US20090297579A1 (en) | Control of Cells and Cell Multipotentiality in Three Dimensional Matrices | |
| US20040171146A1 (en) | Adipose-derived stem cells and lattices | |
| JP2005521402A (ja) | ヒト胚性幹細胞に由来する内皮細胞 | |
| CA2366078A1 (fr) | Cellules souches et reseaux derives de tissus adipeux | |
| Ma et al. | The graft of autologous adipose-derived stem cells in the corneal stromal after mechanic damage | |
| CN104755611A (zh) | 用于生产视网膜色素上皮细胞片层的方法 | |
| Wang et al. | Role of N-cadherin in a niche-mimicking microenvironment for chondrogenesis of mesenchymal stem cells in vitro | |
| Deng et al. | Isolation and chondroinduction of a dermis‐isolated, aggrecan‐sensitive subpopulation with high chondrogenic potential | |
| US20090136559A1 (en) | Chondrocyte Differentiation from Human Embryonic Stem Cells and Their Use in Tissue Engineering | |
| US8431399B2 (en) | Method to restore cartilaginous phenotype of chondrocytes after cultured and expanded in vitro | |
| US8637065B2 (en) | Dermis-derived cells for tissue engineering applications | |
| WO2023167082A1 (fr) | Procédé de production de cellules mésenchymateuses de follicule pileux proliférées et son utilisation | |
| JP2005531298A (ja) | 軟骨の欠損を修復するための再分化細胞 | |
| KR20220080145A (ko) | 연골원성 인간 중간엽 줄기 세포 (msc) 시트 | |
| JP2001224678A (ja) | 軟骨移植用材料の製造方法 | |
| Martinez | Role of Cell-Extracellular Matrix Interactions on Tissue Morphology, Cell Phenotype and Organization in a Salivary Gland Regeneration Model | |
| Zhao et al. | Muscle-derived stem cells differentiate into functional smooth muscle cells for ureter tissue engineering: An experimental study | |
| Pagnani | Elucidating Cell Fate Regulation of the Bone Marrow Vascular Niche Through Development of Engineered Extracellular Matrices | |
| Killaars | Phototunable Hydrogel Materials to Study Epigenetic Remodeling in Mesenchymal Stem Cells | |
| Ann | Application of Size-Based Sorted Zonal Chondrocytes for Articular Cartilage Repair |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |